keyword
MENU ▼
Read by QxMD icon Read
search

Ceftolozane tazobactam

keyword
https://www.readbyqxmd.com/read/29244121/in-vitro-activity-of-ceftolozane-tazobactam-versus-antimicrobial-non-susceptible-pseudomonas-aeruginosa-clinical-isolates-including-mdr-and-xdr-isolates-obtained-from-across-canada-as-part-of-the-canward-study-2008-16
#1
Andrew Walkty, Heather Adam, Melanie Baxter, Philippe Lagacé-Wiens, James A Karlowsky, Daryl J Hoban, George G Zhanel
Objectives: Ceftolozane/tazobactam is a novel β-lactam β-lactamase inhibitor combination with a broad spectrum of activity that includes Pseudomonas aeruginosa. The purpose of this study was to evaluate the in vitro activity of ceftolozane/tazobactam and relevant comparators versus a large collection of antimicrobial non-susceptible P. aeruginosa clinical isolates recovered from patients across Canada (CANWARD, 2008-16). Methods: Susceptibility testing was performed on P...
December 12, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29228202/activity-of-ceftazidime-avibactam-against-problem-enterobacteriaceae-and-pseudomonas-aeruginosa-in-the-uk-2015-16
#2
David M Livermore, Danièle Meunier, Katie L Hopkins, Michel Doumith, Robert Hill, Rachel Pike, Peter Staves, Neil Woodford
Background: Ceftazidime/avibactam combines an established oxyimino-cephalosporin with the first diazabicyclooctane β-lactamase inhibitor to enter clinical use. We reviewed its activity against Gram-negative isolates, predominantly from the UK, referred for resistance investigation in the first year of routine testing, beginning in July 2015. Methods: Isolates were as received from referring laboratories; there is a bias to submit those with suspected carbapenem resistance...
December 8, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29216350/italian-nationwide-survey-on-pseudomonas-aeruginosa-from-invasive-infections-activity-of-ceftolozane-tazobactam-and-comparators-and-molecular-epidemiology-of-carbapenemase-producers
#3
Tommaso Giani, Fabio Arena, Simona Pollini, Vincenzo Di Pilato, Marco Maria D'Andrea, Lucia Henrici De Angelis, Matteo Bassetti, Gian Maria Rossolini
Objectives: Pseudomonas aeruginosa is a major cause of severe healthcare-associated infections and often shows MDR phenotypes. Ceftolozane/tazobactam is a new cephalosporin/β-lactamase inhibitor combination with potent activity against P. aeruginosa. This survey was carried out to evaluate the susceptibility of P. aeruginosa, circulating in Italy, to ceftolozane/tazobactam and comparators and to investigate the molecular epidemiology of carbapenemase-producing strains. Methods: Consecutive non-replicate P...
December 5, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29212704/performance-of-ceftolozane-tazobactam-etest-mic-test-strips-and-disk-diffusion-as-compared-to-reference-broth-microdilution-for-beta-lactam-resistant-pseudomonas-aeruginosa-isolates
#4
Romney M Humphries, Janet A Hindler, Paul Magnano, Annie Wong-Beringer, Robert Tibbetts, Shelley A Miller
The performance of ceftolozane-tazobactam Etest (bioMerieux, Marcy L'Etoile, France), MIC Test Strips (MTS, Liofilchem, Italy) and disk diffusion (Hardy, Santa Ana, CA) were evaluated for a collection of 308 beta-lactam resistant isolates of Pseudomonas aeruginosa recovered from three institutions in Los Angeles, CA. Reference testing was performed by reference broth microdilution (rBMD). MIC and disk results were interpreted using Clinical and Laboratory Standards Institute breakpoints. Overall, 72.5% of isolates were susceptible to C/T by rBMD...
December 6, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/29167294/verification-of-ceftazidime-avibactam-and-ceftolozane-tazobactam-susceptibility-testing-methods-against-carbapenem-resistant-enterobacteriaceae-and-pseudomonas-aeruginosa
#5
Ryan K Shields, Cornelius J Clancy, A William Pasculle, Ellen G Press, Ghady Haidar, Binghua Hao, Liang Chen, Barry N Kreiswirth, M Hong Nguyen
Ceftazidime-avibactam and ceftolozane-tazobactam are newly approved agents for the treatment of infections caused by multidrug-resistant Gram negative bacteria. Resistance to both agents has been described clinically. Susceptibility testing for either agent is unavailable on automated systems. Our objective was to compare disk diffusion and Etest against standard broth microdilution (BMD) methods for testing ceftazidime-avibactam and ceftolozane-tazobactam against a diverse collection of carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa (CRP), respectively...
November 22, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/29159032/use-of-ceftolozane-tazobactam-in-a-cystic-fibrosis-patient-with-multidrug-resistant-pseudomonas-infection-and-renal-insufficiency
#6
Katie Stokem, Jonathan B Zuckerman, David P Nicolau, Minkey Wungwattana, Edmund H Sears
We report the successful use of ceftolozane/tazobactam (C/T) to treat a pulmonary exacerbation in a 35 year old female, post lung transplant, with cystic fibrosis (CF), malnutrition, chronic kidney disease, and multi-drug resistant Pseudomonas aeruginosa infection (MDR PSA). Given the complexity of the clinical profile, we measured drug levels of C/T during treatment of her current exacerbation to determine pharmacokinetics. The patient achieved an estimated ceftolozane peak of 174.1 μg/mL and trough of 9...
2018: Respiratory Medicine Case Reports
https://www.readbyqxmd.com/read/29158144/ceftolozane-tazobactam-in-the-treatment-of-osteomyelitis-and-skin-and-soft-tissue-infections-due-to-extensively-drug-resistant-pseudomonas-aeruginosa-clinical-and-microbiological-outcomes
#7
B Dietl, I Sánchez, P Arcenillas, E Cuchi, L Gómez, F J González de Molina, L Boix-Palop, J Nicolás, E Calbo
Infections due to multidrug-resistant bacteria (MDRB) are currently a clinical challenge, mainly in elderly patients. Ceftolozane/tazobactam spectrum, safety and efficacy make it an attractive option for MDRB beyond the indications approved to date. We report our experience with ceftolozane/tazobactam in 4 cases of osteomyelitis and 3 skin-soft-tissue infections due to extensively-drug-resistant Pseudomonas aeruginosa.
November 17, 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/29149337/mechanisms-leading-to-in-vivo-ceftolozane-tazobactam-resistance-development-during-the-treatment-of-infections-caused-by-mdr-pseudomonas-aeruginosa
#8
Pablo A Fraile-Ribot, Gabriel Cabot, Xavier Mulet, Leonor Periañez, M Luisa Martín-Pena, Carlos Juan, José L Pérez, Antonio Oliver
Objectives: Characterization of the mechanisms driving ceftolozane/tazobactam resistance development in 5 of 47 (10.6%) patients treated for MDR Pseudomonas aeruginosa infections in a Spanish hospital. Methods: Five pairs of ceftolozane/tazobactam-susceptible/resistant P. aeruginosa isolates were studied. MICs were determined by broth microdilution, clonal relatedness was assessed by MLST and resistance mechanisms were investigated by phenotypic and genotypic methods, including WGS...
November 14, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29133568/activity-of-ceftolozane-tazobactam-against-carbapenem-resistant-carbapenemase-non-producing-pseudomonas-aeruginosa-and-associated-resistance-mechanisms
#9
Yu Mi Wi, Kerryl E Greenwood-Quaintance, Audrey N Schuetz, Kwan Soo Ko, Kyong Ran Peck, Jae-Hoon Song, Robin Patel
Although carbapenems are effective for treating serious multidrug-resistant Pseudomonas aeruginosa infections, carbapenem-resistant P. aeruginosa (CRPA) is now being reported worldwide. Ceftolozane/tazobactam (C/T) demonstrates activity against many multidrug-resistant isolates. We evaluated the activity of C/T and compared its activity to that of ceftazidime/avibactam (C/A) using a well-characterized collection of carbapenemase non-producing CRPA isolates. Forty-two carbapenemase non-producing CRPA isolates from a previous study (Int J Antimicrob Agents 2012;40:168-72) were included...
November 13, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29091209/determination-of-alternative-ceftolozane-tazobactam-dosing-regimens-for-patients-with-infections-due-to-pseudomonas-aeruginosa-with-mic-values-between-4-and-32%C3%A2-mg-l
#10
Senthil Natesan, Manjunath P Pai, Thomas P Lodise
Background: Optimization of the antibiotics for patients with infections due to MDR Pseudomonas aeruginosa (MDR-PA) often requires consideration of alternate dose and infusion times that can be influenced by renal function. Objectives: We sought to identify ceftolozane/tazobactam dosing schemes that optimized the probability of target attainment (PTA) against infections due to MDR-PA with ceftolozane/tazobactam MICs between 4 and 32 mg/L across different categories of renal function...
October 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29090091/cost-effectiveness-of-ceftolozane-tazobactam-plus-metronidazole-versus-piperacillin-tazobactam-as-initial-empiric-therapy-for-the-treatment-of-complicated-intra-abdominal-infections-based-on-pathogen-distributions-drawn-from-national-surveillance-data-in-the
#11
Vimalanand S Prabhu, Joseph S Solomkin, Goran Medic, Jason Foo, Rebekah H Borse, Teresa Kauf, Benjamin Miller, Shuvayu S Sen, Anirban Basu
BACKGROUND: The prevalence of antimicrobial resistance among gram-negative pathogens in complicated intra-abdominal infections (cIAIs) has increased. In the absence of timely information on the infecting pathogens and their susceptibilities, local or regional epidemiology may guide initial empirical therapy and reduce treatment failure, length of stay and mortality. The objective of this study was to assess the cost-effectiveness of ceftolozane/tazobactam + metronidazole compared with piperacillin/tazobactam in the treatment of hospitalized US patients with cIAI at risk of infection with resistant pathogens...
2017: Antimicrobial Resistance and Infection Control
https://www.readbyqxmd.com/read/29058126/time-kill-analysis-of-ceftolozane-tazobactam-efficacy-against-mucoid-pseudomonas-aeruginosa-strains-from-cystic-fibrosis-patients
#12
Hana Rac, Kayla R Stover, Jamie L Wagner, S Travis King, Henderson D Warnock, Katie E Barber
INTRODUCTION: Mucoid Pseudomonas aeruginosa (MP) strains in cystic fibrosis (CF) patients are thought to initiate the chronic infection stage of CF and are associated with pulmonary function decline. OBJECTIVES: The purpose of this study was to assess the susceptibility of MP strains to ceftolozane/tazobactam and the efficacy of ceftolozane/tazobactam against MP strains compared with those for standard-of-care antipseudomonal antibiotics. METHODS: Ten clinical isolates of MP from CF patients were tested for susceptibility with Etest and time-kill analysis with ceftolozane/tazobactam compared with ceftazidime, cefepime, ciprofloxacin, meropenem, tobramycin, and polymyxin B...
October 20, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/29039729/antimicrobial-activity-of-ceftolozane-tazobactam-tested-against-enterobacteriaceae-and-pseudomonas-aeruginosa-with-various-resistance-patterns-isolated-in-u-s-hospitals-2013-2016-as-part-of-the-surveillance-program-program-to-assess-ceftolozane-tazobactam-susceptibility
#13
Dee Shortridge, Michael A Pfaller, Mariana Castanheira, Robert K Flamm
This study evaluated the in vitro activity of ceftolozane-tazobactam and comparator agents tested against Enterobacteriaceae and Pseudomonas aeruginosa isolates from hospitalized patients in the United States. Ceftolozane-tazobactam is an antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor. A total of 18,960 organisms (15,223 Enterobacteriaceae and 3,737 P. aeruginosa) were consecutively collected from 32 medical centers located in all nine U.S. census divisions from 2013 to 2016...
October 17, 2017: Microbial Drug Resistance: MDR: Mechanisms, Epidemiology, and Disease
https://www.readbyqxmd.com/read/29021155/effects-of-clinically-meaningful-concentrations-of-anti-pseudomonal-%C3%AE-lactams-on-time-to-detection-and-organism-growth-in-blood-culture-bottles
#14
Mordechai Grupper, David P Nicolau, Jaber Aslanzadeh, Linda K Tanner, Joseph L Kuti
The effectiveness of antimicrobial binding resins present in blood culture (BC) bottles in removing meropenem, ceftolozane/tazobactam, and ceftazidime/avibactam is unknown. We assessed the time to detection (TTD) and growth of 2 Pseudomonas aeruginosa isolates in the presence of clinically meaningful concentrations of these antibiotics. BACTEC Plus Aerobic/F and BacT/ALERT FA Plus BC bottles were inoculated with one of two isolates (1 meropenem susceptible, 1 resistant), followed by fresh whole blood containing the peak, midpoint, or trough plasma concentrations for meropenem, ceftolozane/tazobactam, and ceftazidime/avibactam...
October 11, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/29017262/ceftolozane-tazobactam-for-the-treatment-of-multidrug-resistant-pseudomonas-aeruginosa-infections-clinical-effectiveness-and-evolution-of-resistance
#15
Ghady Haidar, Nathan J Philips, Ryan K Shields, Daniel Snyder, Shaoji Cheng, Brian A Potoski, Yohei Doi, Binghua Hao, Ellen G Press, Vaughn S Cooper, Cornelius J Clancy, M Hong Nguyen
Background: Data on the use of ceftolozane-tazobactam and emergence of ceftolozane-tazobactam resistance during multidrug resistant (MDR)-Pseudomonas aeruginosa infections are limited. Methods: We performed a retrospective study of 21 patients treated with ceftolozane-tazobactam for MDR-P. aeruginosa infections. Whole genome sequencing and quantitative real-time polymerase chain reaction were performed on longitudinal isolates. Results: Median age was 58 years; 9 patients (43%) were transplant recipients...
July 1, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28993338/activity-of-ceftolozane-tazobactam-and-ceftazidime-avibactam-against-beta-lactam-resistant-pseudomonas-aeruginosa-isolates
#16
Romney M Humphries, Janet A Hindler, Annie Wong-Beringer, Shelley A Miller
Ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) minimum inhibitory concentrations were evaluated for a collection of 309 beta-lactam resistant isolates of Pseudomonas aeruginosa recovered from three institutions in Los Angeles, CA. Overall, 12.0% of isolates were susceptible to imipenem, 15.9% to meropenem, 20.7% to piperacillin-tazobactam, 24.6% to ceftazidime and 25.9% to cefepime, 72.5% to C/T and 61.8% to CZA. Among C/T-resistant isolates, 9.1% were CZA-susceptible, whereas 36.4% of CZA-resistant isolates were susceptible to C/T...
October 9, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28993143/ceftolozane-tazobactam-activity-against-drug-resistant-enterobacteriaceae-and-pseudomonas-aeruginosa-causing-health-care-associated-infections-in-the-asia-pacific-region-apac-minus-china-australia-and-new-zealand-report-from-an-antimicrobial-surveillance-program
#17
M A Pfaller, D Shortridge, H S Sader, M Castanheira, R K Flamm
OBJECTIVES: To evaluate the in vitro activity of ceftolozane-tazobactam and comparator agents tested against Enterobacteriaceae and Pseudomonas aeruginosa isolates from patients in the Asia-Pacific region (APAC) with health care associated infections (HAI). Ceftolozane-tazobactam is an antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor. METHODS: A total of 1,963 gram-negative organisms (489 P. aeruginosa and 1,474 Enterobacteriaceae) were consecutively collected using a prevalence-based approach from 14 medical centers in the APAC region...
October 6, 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28980834/successful-treatment-of-three-severe-mdr-or-xdr-pseudomonas-aeruginosa-infections-with-ceftolozane-tazobactam
#18
Marc Xipell, Marta Bodro, Francesc Marco, José A Martínez, Alex Soriano
Ceftolozane/tazobactam is a novel fifth-generation cephalosporin β-lactamase combination with activity against extended-spectrum β-lactamases-producing enterobacteriaceae, and multidrug resistant Pseudomonas aeruginosa. However, clinical experience in real cases caused by these microorganisms is scarce. In this study, we describe three patients with severe infections caused by multidrug resistant and extensively drug-resistant (XDR) P. aeruginosa that were successfully treated with ceftolozane/tazobactam.
October 5, 2017: Future Microbiology
https://www.readbyqxmd.com/read/28961968/susceptibility-of-mdr-pseudomonas-aeruginosa-to-ceftolozane-tazobactam-and-comparison-of-different-susceptibility-testing-methods
#19
Frieder Schaumburg, Stefan Bletz, Alexander Mellmann, Karsten Becker, Evgeny A Idelevich
Background: Infections caused by MDR Pseudomonas aeruginosa are on the rise, particularly in critically ill patients. Therefore, there is a need to evaluate new antimicrobial regimens. The objectives of this study were to investigate the ceftolozane/tazobactam resistance rates of MDR and XDR P. aeruginosa, the underlying resistance genes, the clonal structure and different antimicrobial susceptibility testing (AST) methods regarding their accuracy for ceftolozane/tazobactam testing. Methods: In total, 112 MDR and XDR P...
November 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28947475/pharmacokinetics-pharmacodynamics-of-tazobactam-in-combination-with-cefepime-in-an-in-vitro-infection-model
#20
Brian D VanScoy, David Tenero, Simon Turner, David M Livermore, Jennifer McCauley, Haley Conde, Sujata M Bhavnani, Christopher M Rubino, Paul G Ambrose
We previously demonstrated that for tazobactam administered in combination with ceftolozane, the pharmacokinetic-pharmacodynamic (PK-PD) index that best described tazobactam efficacy was the percentage of the dosing interval that tazobactam concentrations were above a threshold (%T>threshold). Using data from studies of Enterobacteriaceae-producing ESBL, a relationship between tazobactam %T>threshold and reduction in log10 CFU from baseline, for which tazobactam threshold concentration was the product of the isolate's ceftolozane-tazobactam MIC value and 0...
September 25, 2017: Antimicrobial Agents and Chemotherapy
keyword
keyword
118181
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"